Transform Employee
Health with GLP-1 Weight
Loss Solutions

HSA/ FSA Approved

100% 
Online Process

Shipped from 
Southend Pharmacy

The Power of GLP-1 Medications

GLP-1 medications are a breakthrough in weight management, designed to help individuals achieve significant, sustainable results. These medications mimic a natural hormone in the body that regulates appetite and digestion. By targeting specific receptors in the brain, GLP-1s:

Proven Employee Health Benefits

14.9%

Average Weight Loss1

20%

Decrease in Major Adverse 

Cardiac Events2

14.6 cm

Average Decrease in 

Waist Circumference1

Make Weight Loss
Affordable for
Your Team

Allia Health simplifies access to GLP-1 medications, ensuring employees have the tools they need to achieve lasting health improvements.

HSA/FSA-Approved

Employees can use their benefits to cover medication costs.

Direct Shipping

Medications are shipped directly from our compounding pharmacy partner, Southend Pharmacy, saving time and reducing out-of-pocket expenses.

100% Online Process

From online approval to doorstep delivery, we make accessing GLP-1 medications seamless and efficient for employees.

Exclusive Discounts

for Employer Partners

We offer GLP-1 medications at a reduced price for participating employers, making weight loss solutions more accessible for your team.

A Strategic Investment in Make Workforce Health

Attract and
Retain Talent

Stand out as an employer that prioritizes employee health.

Lower
Healthcare Costs

Address weight-related health risks to reduce high-cost claims over time.

Increase
Engagement

Employees who feel supported are more loyal, engaged, and productive.
By partnering with Allia Health, you’re investing in healthier employees — and a healthier business.

Support Your Workforce with Allia Health

Give your employees access to the weight loss solutions they want and need while improving health outcomes and driving measurable results for your business.
Request a Demo
References:
[1] Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831 [2] Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69. doi:10.1016/j.ahj.2020.07.008